Skip to content

May 14, 2026

ChatGPT Image May 7, 2026, 07_11_28 PM

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Regulatory
Regulatory round-up: A month of key FDA approvals for cancer drugs

Regulatory

Regulatory round-up: A month of key FDA approvals for cancer drugs

Pharmaceutical Technology

Four cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications.

Read full story

pharminent May 14, 2026 (Last updated: May 14, 2026)

Pharmaceutical Technology

Four cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications.

Read full story

Post navigation

Previous: Zydus to acquire Assertio in $166m deal

Next: Regenxbio’s Duchenne gene therapy clears phase 3 hurdle

Related Stories

Regulatory

With new data, Regenxbio to seek FDA approval of Duchenne gene therapy

pharminent May 14, 2026

Regulatory

Pfizer receives EC approval for Hympavzi to treat haemophilia

pharminent May 14, 2026

Regulatory

Third Circuit Affirms Denial of Stelara Biosimilar Injunction

pharminent May 11, 2026

You May Have Missed

Pipeline

Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism

pharminent May 14, 2026

Regulatory

With new data, Regenxbio to seek FDA approval of Duchenne gene therapy

pharminent May 14, 2026

Policy / Pricing

Biotech leaders pitch Pazdur as next FDA chief

pharminent May 14, 2026

M&A / Deals

Degron adds $40M to series A, supporting immunology plans for molecular glue platform

pharminent May 14, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.